Bladder cancer - suspected
|
|
- Owen Mitchell
- 5 years ago
- Views:
Transcription
1 Background information Information resources for patients and carers Updates to this care map Bladder cancer - clinical presentation History Examination Consider differential diagnoses Clinical indications for urgent referral Refer urgently to urologist (within 2 weeks) Investigations Go to bladder cancer - diagnosis Haematuria with urinary tract infection (UTI) symptoms Unexplained nonvisible haematuria If no infection found, refer urgently to specialist urological cancer team Treat if infection confirmed Age 50 years or over - consider urgent referral to specialist urological cancer team Age under 50 years - test for proteinuria and serum creatinine Recurrent infection Consider urgent referral to specialist urological cancer team Refer urgently to specialist urological cancer team (within 2 weeks) Go to bladder cancer - diagnosis Proteinuria and raised serum creatinine Refer to renal physician Values normal Refer to urologist Refer urgently to specialist urological cancer team (within 2 weeks) Go to bladder cancer - diagnosis For terms of use please see our Terms and Conditions Page 1 of 10
2 1 Background information Scope: diagnosis and management of bladder cancer, both superficial and muscle-invasive urothelial carcinomas in primary and secondary care settings, for adults above age 18 years referral criteria for non-visible haematuria consideration of chemotherapy and radical radiotherapy treatment options discussion of bladder tumour resection as well as indications for cystoscopy treatment options for metastatic disease palliative care referral criteria Definition: over 90% of cancers of the urinary bladder are urothelial carcinoma (previously known as transitional cell carcinoma). Nonmuscle-invasive tumours are most common [1] non-muscle invasive tumours, ie no spread beyond the lamina propria, include: Ta non-invasive papillary carcinoma Tis carcinoma in situ ('flat tumour'): non-invasive, flat, full thickness, high grade dysplastic change in the urothelium high risk of progression to invasive disease T1 tumour invades subepithelial connective tissue (lamina propria) muscle invasive tumours, ie spread beyond the lamina propria, include: T2 tumour invades detrusor muscle T3 tumour invades perivesical tissue T4 tumour invades any of the following: prostate uterus vagina pelvic wall abdominal wall Incidence and prevalence: bladder carcinoma is the second most common malignancy of the urinary tract unusual in people below age 40 years [3] in males, incidence rises steeply with each decade between age years [3]: 1.99 per 100,000 in those age years [18] per 100,000 in those age years [18] per 100,000 in those age years [18] in females, incidence shows a similar rate of increase with age, with the proportion in each age group less than half the corresponding figures for males [3] Risk factors: cigarette smoke: significant dose-response relationship between the lifetime number of cigarettes smoked and risk of bladder cancer: triples the risk of developing bladder cancer smokers are 2-5 times more likely to develop bladder cancer than non-smokers [3] causes approximately 50-65% and 20-30% of cases in males and females respectively [4] occupational exposure to carcinogenic chemicals thought to account for up to 20% of cases [3]: highest risk occupations are those associated with high levels of exposure to: rubber dyes plastics related chemicals can cause bladder cancer 5-50 (typically 10-15) years later increasing age gender: estimated male to female ratio is 3.8:1 females more likely to be diagnosed with primary muscle invasive disease than males history of previous radiotherapy or chemotherapy (eg cyclophosphamide) long-term use of indwelling bladder catheters long-term use of chlorinated drinking water may increase the risk up to two-fold For terms of use please see our Terms and Conditions Page 2 of 10
3 chronic urinary tract infection (UTI): bladder schistosomiasis is considered a definitive cause of squamous cell carcinoma of the bladder dietary factors Prognosis: determined by depth to which tumour has invaded the bladder wall [5] 5-year survival in England, based on data, is [18]: 61% for men 49% for women [1] Lamm D, Heeley M. Bladder cancer. BMJ Best Practice; [2] Contributors invited by Map of Medicine; [3] National Institute for Health and Clinical Excellence (NICE). Guidance on cancer services: improving outcomes in urological cancers the manual. London: NICE; [4] European Association of Urology (EAU). Guidelines on bladder cancer: muscle-invasive and metastatic. The Netherlands: EAU; [5] European Association of Urology (EAU). Guidelines on TaT1 (non-muscle invasive) bladder cancer. The Netherlands: EAU; [6] Scottish Intercollegiate Guidelines Network (SIGN). Management of transitional cell carcinoma of the bladder. SIGN publication no. 85. Edinburgh: SIGN; [18] Contributors representing the National Cancer Action Team; Information resources for patients and carers Patients and carers in England can access this care map through NHS Choices at map/bladder_cancer1.html The following resources have been produced by organisations certified by The Information Standard: 'Bladder cancer' (URL) from Bupa at 'Bladder cancer' (URL) from Cancer Help UK at 'Bladder cancers' (URL) from Datapharm at 'Bladder cancer' (URL) from Macmillan Cancer Support at 'Bladder cancer' (PDF) from Patient UK at 'Bladder cancer - risk factors' (URL) from Cancer Research UK at 'Transurethral resection of bladder tumour (TURBT)' (URL) from Bupa at Information for carers and people with disabilities is available at: 'Caring for someone' (URL) from Directgov at 'Disabled people' (URL) from Directgov at Explanations of clinical laboratory tests used in diagnosis and treatment are available at 'Understanding Your Tests (URL) from Lab Tests Online-UK at The Map of Medicine is committed to providing high quality health and social care information for patients and carers. For details on how these resources are identified, please see Map of Medicine Patient and Carer Information. NB: This information appears on each page of this care map. 3 Updates to this care map Date of publication: 29-Apr-2011 Interim update: Definition of proteinuria added in line with the following reference: [20] National Institute for Health and Clinical Evidence (NICE). Early identification and management of chronic kidney disease in adults in primary and secondary care. Clinical guideline 73. London: NICE; Interim update: 31-Jan-2011 The clinical content of this care map has been accredited by the National Cancer Action Team Date of publication: 29-Oct-2010 Interim update: For terms of use please see our Terms and Conditions Page 3 of 10
4 This care map has been updated according to feedback from the National Cancer Action Team (NCAT): [18] Contributors representing the National Cancer Action Team; Date of publication: 30-Jul-2010 Three floating information points now appear at the top of each care map page. These provide: easy access to scope and background information on each page of the care map whilst reducing repetition between care points easy access to patient resources/leaflets information on care map updates This care map was updated in line with the following guidelines: [3] National Institute for Health and Clinical Excellence (NICE). Guidance on cancer services: improving outcomes in urological cancers the manual. London: NICE; [4] European Association of Urology (EAU). Guidelines on bladder cancer: muscle-invasive and metastatic. The Netherlands: EAU; [5] European Association of Urology (EAU). Guidelines on TaT1 (non-muscle invasive) bladder cancer. The Netherlands: EAU; [6] Scottish Intercollegiate Guidelines Network (SIGN). Management of transitional cell carcinoma of the bladder. SIGN publication no. 85. Edinburgh: SIGN; children. Clinical guideline 27. London: NICE; [9] Clinical Knowledge Summaries (CKS). Urological cancer suspected. Version 1.0. Newcastle upon Tyne: CKS; [11] Hall MC, Chang SS, Dalbagni G et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007; 178: [13] National Institute for Health and Clinical Excellence (NICE). Intravesical microwave hyperthermia with intravesical chemotherapy for superficial bladder cancer. Interventional procedure guidance 235. London: NICE; c [14] National Institute for Health and Clinical Excellence (NICE). Electrically-stimulated intravesical chemotherapy for superficial bladder cancer. Interventional procedure guidance 277. London: NICE; [17] Cancer Care Ontario. Use of neoadjuvant chemotherapy in transitional cell carcinoma of the bladder. Toronto, ON: Cancer Care Ontario; Further information was provided by the following references: [1,2,8,10,12,15,16]. For more information, please see the care map's Provenance certificate. Practice-based knowledge has been contributed to this care map by: Dr Anne E Kiltie: Clinical Group Leader/Honorary Consultant Clinical Oncologist, Gray Institute for Radiation Oncology and Biology, Oxford, UK Prof Howard Kynaston: Consultant in urology, Cardiff University Department of Surgery, Cardiff, Wales Selected members of the Clinical Editorial team and Fellows The care map has been completely restructured and redrafted in line with the Map of Medicine editorial methodology and to bring it in line with current clinical practice. NB: This information appears on each page of this care map. 4 Bladder cancer - clinical presentation Features include: visible haematuria (blood in the urine): present in 80-90% of patients [3,5] may be intermittent, but a single episode of haematuria can signal the presence of cancer non-visible haematuria: better predictor of cancer in older men more likely to be pathological in young men is less likely to be associated with any pathology in primary care, painful, urgent, or frequent urination (dysuria): usually suggests a urinary tract infection (UTI) and is rarely due to bladder cancer painful urination may indicate a bladder outlet obstruction 20-30% of patients eventually diagnosed with bladder cancer have these symptoms at presentation [4] Always consider the diagnosis, especially if symptoms are: associated with atypical features persistent refractory to UTI treatment Advanced disease may involve: For terms of use please see our Terms and Conditions Page 4 of 10
5 abdominal or pelvic mass (unusual at presentation) bone pain pelvic pain oedema of the lower limbs due to compression of the iliac vessels pain in the flank due to obstruction of the ureter weight loss cachexia [3] National Institute for Health and Clinical Excellence (NICE). Guidance on cancer services: improving outcomes in urological cancers the manual. London: NICE; [4] European Association of Urology (EAU). Guidelines on bladder cancer: muscle-invasive and metastatic. The Netherlands: EAU; [5] European Association of Urology (EAU). Guidelines on TaT1 (non-muscle invasive) bladder cancer. The Netherlands: EAU; History Ask patient about: blood visible in urine dysuria, urgency, or frequency systemic symptoms of urinary tract infection (UTI) palpable abdominal or pelvic mass bone, pelvic, or flank pain lymphadenopathy history of: smoking work in the rubber, painting, or metal industries radiotherapy or chemotherapy, eg cyclophosphamide This information was drawn from the following reference: 6 Examination Examination is rarely revealing of bladder tumours an examination should include: pelvic examination to assess prostate or pelvic mass assessment for lymphadenopathy urinalysis This information was drawn from the following references: [4] European Association of Urology (EAU). Guidelines on bladder cancer: muscle-invasive and metastatic. The Netherlands: EAU; [5] European Association of Urology (EAU). Guidelines on TaT1 (non-muscle invasive) bladder cancer. The Netherlands: EAU; Consider differential diagnoses Possible differential diagnoses for bladder cancer include: kidney cancer see 'Kidney cancer' care map urinary tract infection (UTI) non-infectious haemorrhagic cystitis For terms of use please see our Terms and Conditions Page 5 of 10
6 kidney stones see 'Kidney stones' care map prostate cancer see 'Prostate cancer' care map benign prostatic hyperplasia see 'Male lower urinary tract symptoms' care map This information was drawn from the following references: [4] European Association of Urology (EAU). Guidelines on bladder cancer: muscle-invasive and metastatic. The Netherlands: EAU; [8] Map of Medicine (MoM) Clinical Editorial team and Fellows. London: MoM; Clinical indications for urgent referral Refer any patient presenting with any one of the following to the local specialist team for urological cancers patients should be seen within 2 weeks [4]: painless visible haematuria in the absence of symptoms suggesting a urinary tract infection (UTI) persistent UTI and haematuria (either visible or non-visible) particularly in those over age 40 years an abdominal mass with location consistent with a urinary tract origin palpable renal mass solid renal masses on imaging [4] National Institute for Health and Clinical Excellence (NICE). Referral guidelines for suspected cancer in adults and 10 Investigations Investigations should include the following [3]: urinalysis check particularly for: haematuria proteinuria leucocytosis urine culture if infection is suspected urine microscopy if haematuria is present but no signs of UTI, consider: red cell morphology on urinary sediment (morning sample) urine cytology (note high rate of false positives) [4,5] serum creatinine and urea [7,9] full blood count (FBC) [3] National Institute for Health and Clinical Excellence (NICE). Guidance on cancer services: improving outcomes in urological cancers the manual. London: NICE; [4] European Association of Urology (EAU). Guidelines on bladder cancer: muscle-invasive and metastatic. The Netherlands: EAU; [5] European Association of Urology (EAU). Guidelines on TaT1 (non-muscle invasive) bladder cancer. The Netherlands: EAU; [9] Clinical Knowledge Summaries (CKS). Urological cancer suspected. Version 1.0. Newcastle upon Tyne: CKS; Haematuria with urinary tract infection (UTI) symptoms Patient has blood in urine and symptoms suggesting a urinary tract infection (UTI). 12 Unexplained non-visible haematuria For terms of use please see our Terms and Conditions Page 6 of 10
7 Non-visible haematuria is usually identified microscopically or chemically by dipstick there should be no frank blood in the urine [8]. Reference: [8] Map of Medicine (MoM) Clinical Editorial team and Fellows. London: MoM; Age 50 years or over - consider urgent referral to specialist urological cancer team Consider referral to the local specialist urological cancer team patients should be seen within 2 weeks [6,7,9]: for patients age 50 years and above; with unexplained non-visible haematuria [6] Scottish Intercollegiate Guidelines Network (SIGN). Management of transitional cell carcinoma of the bladder. SIGN publication no. 85. Edinburgh: SIGN; [9] Clinical Knowledge Summaries (CKS). Urological cancer suspected. Version 1.0. Newcastle upon Tyne: CKS; Age under 50 years - test for proteinuria and serum creatinine Test patients age 50 years and below with unexplained non-visible haematuria for [7,9]: proteinuria serum creatinine level [9] Clinical Knowledge Summaries (CKS). Urological cancer suspected. Version 1.0. Newcastle upon Tyne: CKS; If no infection found, refer urgently to specialist urological cancer team Patients with unexplained visible haematuria should be referred to a urologist within the local multidisciplinary team (MDT) for urological cancers and seen within 2 weeks [7]. Reference: 16 Treat if infection confirmed Treat the urinary tract infection (UTI) [7]: if the infection and features (including haematuria) do not resolve or if it recurs, consider referral to specialist urological cancer team Reference: 17 Recurrent infection For terms of use please see our Terms and Conditions Page 7 of 10
8 Recurrent urinary tract infection (UTI) is infection that is initially treated but returns at least once [8]. Reference: [8] Map of Medicine (MoM) Clinical Editorial team and Fellows. London: MoM; Proteinuria and raised serum creatinine Consider referral to a renal physician [6,7,9]: for patients below age 50 years; with unexplained non-visible haematuria; and proteinuria and raised serum creatinine Significant proteinuria [18]: in people without diabetes, consider clinically significant proteinuria to be present when the albumin/creatinine ratio (ACR) is 30mg/mmol or more (this is approximately equivalent protein:creatinine ratio 50mg/mmol, or a urinary protein excretion 0.5g/24hours or more) in people with diabetes, consider microalbuminuria (ACR more than 2.5mg/mmol in men and ACR more than 3.5mg/mmol in women) to be clinically significant [6] Scottish Intercollegiate Guidelines Network (SIGN). Management of transitional cell carcinoma of the bladder. SIGN publication no. 85. Edinburgh: SIGN; [9] Clinical Knowledge Summaries (CKS). Urological cancer suspected. Version 1.0. Newcastle upon Tyne: CKS; [20] National Institute for Health and Clinical Evidence (NICE). Early identification and management of chronic kidney disease in adults in primary and secondary care. Clinical guideline 73. London: NICE; Values normal Consider non-urgent referral to a urologist [6,7,9]: for patients below age 50 years; with unexplained non-visible haematuria; but no proteinuria and normal serum creatinine [6] Scottish Intercollegiate Guidelines Network (SIGN). Management of transitional cell carcinoma of the bladder. SIGN publication no. 85. Edinburgh: SIGN; [9] Clinical Knowledge Summaries (CKS). Urological cancer suspected. Version 1.0. Newcastle upon Tyne: CKS; Consider urgent referral to specialist urological cancer team If a urinary tract infection (UTI) associated with visible haematuria does not resolve on treatment, or recurs, refer patient urgently (to be seen within 2 weeks) to a urologist within the local multidisciplinary team (MDT) for urological cancers [7]: this is to exclude malignancy as a first priority, although there are a variety of benign causes for persistent or recurrent UTI Reference: For terms of use please see our Terms and Conditions Page 8 of 10
9 Key Dates, by International Valid until: 29-Feb-2012 Accreditations The care map is accredited by: National Cancer Action Team (NCAT): Disclaimer The care map is accredited by: The Chief Knowledge Officer of the NHS: Disclaimer Evidence summary for This pathway has been developed according to the Map of Medicine editorial methodology ( whatisthemap/editorialmethodology). The content of this pathway is based on high-quality guidelines [1,3-7,9,11,13,14,17,20], critically appraised meta-analyses and systematic reviews [12,15,16] and safety and prescribing information [10]. Practice-based knowledge has been added by contributors with front-line clinical experience [2,8,18], including any literature endorsed by the contributor group [19]. The evidence-based, practice-informed pathway has been peer-reviewed by central committees within stakeholder groups. Search date: Mar-2010 References This is a list of all the references that have passed critical appraisal for use in the care map Bladder cancer ID Reference 1 Lamm D, Heeley M. Bladder cancer. BMJ Best Practice; Contributors invited by Map of Medicine National Institute of Health and Clinical Excellence (NICE). Guidance on cancer services: improving outcomes in urological cancers - the manual. London: NICE; European Association Urology (EAU). Guidelines on bladder cancer: muscle-invasive and metastatic. The Netherlands: EAU; European Association Urology (EAU). Guidelines on TaT1 (non-muscle invasive) bladder cancer. The Netherlands: EAU; Scottish Intercollegiate Guidelines Network (SIGN). Management of transitional cell carcinoma of the bladder. Clinical Guideline 85. Edinburgh: SIGN; National Institute for Health and Clinical Excellence (NICE). Referral guidelines for suspected cancer. Clinical guideline 27. London: NICE; Map of Medicine (MoM) Clinical Editorial team and Fellows. London: MoM; Clinical Knowledge Summaries (CKS). Urological cancer - suspected. Version 1.0. Newcastle upon Tyne: CKS; Department of Health (DH). Going further on cancer waits. London: DH; Hall MC, Chang SS, Dalbagni G et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007; 178: Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a metaanalysis of published results of randomized clinical trials. J Urol 2004; 171: , quiz. For terms of use please see our Terms and Conditions Page 9 of 10
10 ID Reference 13 National Institute for Health and Clinical Excellence (NICE). Intravesical microwave hyperthermia with intravesical chemotherapy for superficial bladder cancer. Interventional procedure guidance 235. London: NICE; National Institute for Health and Clinical Excellence (NICE). Electrically-stimulated intravesical chemotherapy for superficial bladder cancer. Interventional procedure 277. London: NICE; Han RF, Pan JG. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006; 67: Babjuk M, Oosterlinck W, Sylvester R. Guidelines on TaT1 (non-muscle invasive) bladder cancer. The Netherlands: European Association of Urology (EAU); Cancer Care Ontario. Use of neoadjuvant chemotherapy in transitional cell carcinoma of the bladder. Toronto, ON: Cancer Care Ontario; Contributors representing the National Cancer Action Team Donat SM, Herr HW, Bajorin DF et al. Methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and cystectomy for unresectable bladder cancer. J Urol 1996; 156: National Institute for Health and Clinical Excellence (NICE). Early identification and management of chronic kidney disease in adults in primary and secondary care. Clinical guideline 73. London: NICE; Disclaimers National Cancer Action Team (NCAT) It is not the function of the National Cancer Action Team to substitute for the role of the clinician, but to support the clinician in enabling access to know-how and knowledge. Users of the Map of Medicine are therefore urged to use their own professional judgement to ensure that the patient receives the best possible care. Whilst reasonable efforts have been made to ensure the accuracy of the information on this online clinical knowledge resource, we cannot guarantee its correctness or completeness. The information on the Map of Medicine is subject to change and we cannot guarantee that it is up-to-date. The Chief Knowledge Officer of the NHS It is not the function of the Chief Knowledge Officer of the NHS to substitute for the role of the clinician, but to support the clinician in enabling access to know-how and knowledge. Users of the Map of Medicine are therefore urged to use their own professional judgement to ensure that the patient receives the best possible care. Whilst reasonable efforts have been made to ensure the accuracy of the information on this online clinical knowledge resource, we cannot guarantee its correctness or completeness. The information on the Map of Medicine is subject to change and we cannot guarantee that it is up-to-date. For terms of use please see our Terms and Conditions Page 10 of 10
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction
More informationStaging and Grading Last Updated Friday, 14 November 2008
Staging and Grading Last Updated Friday, 14 November 2008 There is a staging graph below Blood in the urine is the most common indication that something is wrong. Often one will experience pain or difficulty
More informationUpdate on Haematuria and Bladder Cancer
Update on Haematuria and Bladder Cancer Hugh Mostafid FRCS(urol) FEBU Consultant Urologist, Royal Surrey County Hospital and Honorary Senior Lecturer, University of Surrey Guildford None Declarations Recent
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationGuidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationBLADDER CANCER: PATIENT INFORMATION
BLADDER CANCER: PATIENT INFORMATION The bladder is the balloon like organ located in the pelvis that stores and empties urine. Urine is produced by the kidneys, is conducted to the bladder by the ureters,
More informationH(a)ematuria. FX Keeley Consultant Urologist Bristol Urological Institute
H(a)ematuria FX Keeley Consultant Urologist Bristol Urological Institute From Philadelphia to Bristol, England Southmead Hospital, 1916 Southmead Hospital, 2013 Southmead Hospital, 2014 H(a)ematuria Blood
More informationHaematuria and Bladder Cancer
Haematuria and Bladder Cancer Dr Pardeep Kumar Consultant Urological Surgeon Haematuria 3 Haematuria Macroscopic vs Microscopic Painful vs Painless Concurrent abdo pain/urinary symptoms Previous testing?
More informationCare of bladder cancer patients diagnosed in Northern Ireland 2010 & 2011 (Summary)
Care of bladder cancer patients diagnosed in 2010 & 2011 (Summary) Bannon, F., Ranaghan, L., & Gavin, A. (2014). Care of bladder cancer patients diagnosed in 2010 & 2011 (Summary). N. Cancer Registry,
More informationBladder Cancer Guidelines
Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationLower Urinary Tract Infection (UTI) in Males
Lower Urinary Tract Infection (UTI) in Males Clinical presentation For patients in care homes see UTI in adults where IV Antibiotics in the community may be appropriate (under development) History and
More informationGuidelines for the Management of Bladder Cancer
Guidelines for the Management of Bladder Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Version 3 and 4 Sections 5.2 and 8 updated Page 1 of 9 1. Scope of
More informationBLADDER TUMOURS A REVIEW OF 150 PATIENTS TREATED AT THE INSTITUTE OF UROLOGY AND NEPHROLOGY GENERAL HOSPITAL KUALA LUMPUR
Med. J. Malaysia Vol. 38. No. I March 1983. BLADDER TUMOURS A REVIEW OF 150 PATIENTS TREATED AT THE INSTITUTE OF UROLOGY AND NEPHROLOGY GENERAL HOSPITAL KUALA LUMPUR ZAKRIYA MAHAMOOTH HUSSAIN AWANG SUMMARY
More informationJoseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016
BLADDER CANCER Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER = UROTHELIAL CANCER Antiquated term is Transitional Cell Carcinoma
More informationHaematuria and Modern Bladder Cancer Treatment
Haematuria and Modern Bladder Cancer Treatment Mr Nikhil Vasdev MBBS MRCS MCh(Urol) FRCS(Urol) RCSEng/BAUS Robotic Fellowship Accredited and Trained Consultant Urological and Robotic Surgeon Hertfordshire
More informationA patient with recurrent bladder cancer presents with the following history:
MP/H Quiz A patient with recurrent bladder cancer presents with the following history: 9/23/06 TURB 1/12/07 TURB 4/1/07 TURB 7/12/07 TURB 11/14/07 Non-invasive papillary transitional cell carcinoma from
More informationClinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer
International Journal of Urology (2011) 18, 439 443 doi: 10.1111/j.1442-2042.2011.02766.x Original Article: Clinical Investigationiju_2766 439..443 Clinical significance of immediate urine cytology after
More informationBladder Cancer Canada November 21st, Bladder Cancer 2018: A brighter light at the end of the cystoscope
Bladder Cancer Canada November 21st, 2018 Bladder Cancer 2018: A brighter light at the end of the cystoscope Chris Morash MD FRCSC Associate Professor, University of Ottawa Head, Urological Oncology Bladder
More informationThe innovative aspect is that it detects bladder cancer based on the novel biomarker, minichromosome maintenance complex component 5 (MCM5).
pat hways ADXBLADDER for detecting bladder cancer Medtech innovation briefing Published: 12 April 2019 nice.org.uk/guidance/mib180 Summary The technology described in this briefing is ADXBLADDER. It is
More informationMODULE 5: HEMATURIA LEARNING OBJECTIVES DEFINITION. KEY WORDS: Hematuria, Cystoscopy, Urine Cytology, UTI, bladder cancer
MODULE 5: HEMATURIA KEY WORDS: Hematuria, Cystoscopy, Urine Cytology, UTI, bladder cancer LEARNING OBJECTIVES At the end of this clerkship, the learner will be able to: 1. Define microscopic hematuria.
More informationNMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland
NMIBC Piotr Jarzemski Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland 71 year old male patient was admitted to the Department of Urology First TURBT - 2 months prior to the hospitalisation.
More informationRenal tumors of adults
Renal tumors of adults Urinary Tract Tumors 2%-3% of all cancers in adults. The most common malignant tumor of the kidney is renal cell carcinoma. Tumors of the lower urinary tract are twice as common
More informationCosting report: Bladder cancer
Putting NICE guidance into practice Costing report: Bladder cancer Implementing the NICE guideline on bladder cancer (NG2) Published: February 2015 Updated September 2015 to update the unit cost of transurethral
More informationCarcinoma of the Urinary Bladder Histopathology
Carcinoma of the Urinary Bladder Histopathology Reporting Proforma (Radical & Partial Cystectomy, Cystoprostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family
More information10/23/2012 CASE STUDIES: RENAL AND UROLOGIC IMPAIRMENTS. 1) Are there any clues from this history that suggest a particular diagnosis?
Case # 1 An underwriter enters your office, hands you a sheet of paper, and asks What do you think? Can we make an offer? You look at the paper and see it s lab results on a 60 year male looking for $500,000
More information6 UROLOGICAL CANCERS. 6.1 Key Points
6 UROLOGICAL CANCERS 6.1 Key Points Prostate Cancer Commonest cancer in males in Scotland Approximately 99% of cases occur in men aged > 50 years About 40% of cases present in men aged < 70 years when
More information3.1 Investigations for Patients Presenting with Haematuria Table 1
3.1 Investigations for Patients Presenting with Haematuria Table 1 Patients at risk of bacterial endocarditis should be given antibiotic prophylaxis as per local guidelines. Patients with heart valve replacements
More informationCYSVIEW. CONFIDENCE AT FIRST SIGHT
CYSVIEW. CONFIDENCE AT FIRST SIGHT Blue Light Cystoscopy with CYSVIEW Cysview Indication Cysview is an optical imaging agent indicated for use in the cystoscopic detection of non-muscle invasive papillary
More informationMEDitorial March Bladder Cancer
MEDitorial March 2010 Bladder Cancer Last month, my article addressed the issue of blood in the urine ( hematuria ). A concerning cause of hematuria is bladder cancer, a variably malignant tumor starting
More informationBladder Cancer in Primary Care. Dr Penny Kehagioglou Consultant Clinical Oncologist
Bladder Cancer in Primary Care Dr Penny Kehagioglou Consultant Clinical Oncologist Objectives Patient presentation in primary care Investigating bladder cancer Management of bladder cancer Differential
More informationUrological Tumours 1 Kidney tumours 2 Bladder tumours
Urological Tumours 1 Kidney tumours 2 Bladder tumours Tim Bracey SpR Histopathology Derriford Hospital Kidney tumours What are we going to talk about?! Anatomy of urinary tract! Types of kidney tumours!
More informationEAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER
EU GUIDELINES ON NON-MUSLE INVSIVE (TaT1, IS) LDDER NER (Limited text update March 2017) M. abjuk (hair), M. urger (Vice-hair), E. ompérat, P. Gontero,.H. Mostafid, J. Palou,.W.G. van Rhijn, M. Rouprêt,
More informationUROTHELIAL CELL CANCER
UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute
More informationUpdate on bladder cancer diagnosis and management
7 Update on bladder cancer diagnosis and management RICHARD T. BRYAN Although the basis of the diagnosis and management of urothelial bladder cancer has remained unchanged for two decades or more, there
More informationQ&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series
Collecting Cancer Data Bladder & Renal Pelvis NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationSymptoms, Diagnosis and Classification
Patient Information English 2 Symptoms, Diagnosis and Classification The underlined terms are listed in the glossary. Signs and symptoms Blood in the urine is the most common symptom when a bladder tumour
More informationDiagnosis and classification
Patient Information English 2 Diagnosis and classification The underlined terms are listed in the glossary. Signs and symptoms Blood in the urine is the most common symptom when a bladder tumour is present.
More informationInformation for Patients. Bladder Cancer. English
Information for Patients Bladder Cancer English Table of contents What is the function of the bladder?... 3 What is bladder cancer?... 3 What causes bladder cancer?... 3 Stages of the disease... 3 Risk
More informationKidney, Bladder and Prostate Neoplasia. David Bingham MD
Kidney, Bladder and Prostate Neoplasia David Bingham MD typical malignant cytology of bladder washings 1 benign 2 malignant typical malignant cytology of bladder washings b Bladder tumor Non invasive papillary
More informationSUPERFICIAL BLADDER CANCER MANAGEMENT
A CME Webcast/TELECONFERENCE Case by Case: CRITICAL ISSUES IN SUPERFICIAL BLADDER CANCER MANAGEMENT An Interactive Case Format with Instant Audience Polling APRIL-MAY 2005 CME Program Slide Book Sponsored
More informationGlossary of Terms Primary Urethral Cancer
Patient Information English Glossary of Terms Primary Urethral Cancer Advanced cancer A tumour that grows into deeper layers of tissue, adjacent organs, or surrounding muscles. Anaesthesia (general, spinal,
More informationRadical Cystectomy Often Too Late? Yes, But...
european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer
More informationBLADDER CANCER CONTENT CREATED BY. Learn more at
BLADDER CANCER CONTENT CREATED BY Learn more at www.health.harvard.edu TALK TO YOUR DOCTOR Table of Contents WHAT IS BLADDER CANCER? 4 TYPES OF BLADDER CANCER 5 GRADING AND STAGING 8 TREATMENT OVERVIEW
More informationCitation International journal of urology (2. Right which has been published in final f
Title Novel constant-pressure irrigation of renal pelvic tumors after ipsila Nakamura, Kenji; Terada, Naoki; Sug Author(s) Toshinori; Matsui, Yoshiyuki; Imamu Kazutoshi; Kamba, Tomomi; Yoshimura Citation
More informationGuidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS)
Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt European Association of Urology 2011 TABLE OF CONTENTS
More informationTrans Urethral Resection of Bladder Tumour
Trans Urethral Resection of Bladder Tumour Department of Urology 2 Patient Information Contents Where is the bladder and what does it do? 3 What is non invasive cancer of the bladder? 4 How is bladder
More informationThe Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis
Bladder Cancer 2 (2016) 273 278 DOI 10.3233/BLC-160048 IOS Press Research Report 273 The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis Ashish
More informationThe Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
30 th Congress of the European Society of Pathology Tuesday, September 11, 2018 The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
More informationPathology Driving Decisions
Pathology Driving Decisions Part I: Understanding Your Diagnosis and Your Treatment Options May 7, 2018 Presented by: Dr. Matthew Mossanen completed his college and medical school training at UCLA. He
More informationHey Doc, there s blood in my urine Evaluation of hematuria. Christian S. Kuhr, MD FACS May 4, 2018
Hey Doc, there s blood in my urine Evaluation of hematuria Christian S. Kuhr, MD FACS May 4, 2018 Objectives Understand the algorithm for hematuria evaluation Know the differential diagnosis for hematuria
More informationManagement of Superficial Bladder Cancer Douglas S. Scherr, M.D.
Management of Superficial Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.
More informationThe pathology of bladder cancer
1 The pathology of bladder cancer Charles Jameson Introduction Carcinoma of the bladder is the seventh most common cancer worldwide [1]. It comprises 3.2% of all cancers, with an estimated 260 000 new
More informationClinical Commissioning Policy Proposition: Robotic Assisted Surgery for Bladder Cancer
Clinical Commissioning Policy Proposition: Robotic Assisted Surgery for Bladder Cancer Reference: NHS England B14X08 Information Reader Box (IRB) to be inserted on inside front cover for documents of 6
More informationUrinary Bladder, Ureter, and Renal Pelvis
Urinary Bladder, Ureter, and Renal Pelvis Protocol applies to all carcinomas of the urinary bladder, ureter, and renal pelvis. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition Procedures
More informationBladder cancer. Epidemiology and presentation
clinical Bladder cancer Ranjan Arianayagam ohan Arianayagam Prem Rashid Current management Background Over 2000 cases of bladder cancer were diagnosed in Australia in 2005. Bladder cancer is a relatively
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of electrically-stimulated intravesical chemotherapy for superficial bladder
More information9/13/2017. Highgate Private Hospital & Whittington Health NHS Trust. London Cancer Urology Guidelines for Target Referrals. Urological Cancer Groups
London Cancer Urology Guidelines for Target Referrals Mr Paul Erotocritou MBBS BSc MSc, MRCS, FRCS (Urol)Eng Highgate Private Hospital & Whittington Health NHS Trust Urological Cancer Groups 5 groups:
More informationInformation for Patients. Primary urethral cancer. English
Information for Patients Primary urethral cancer English Table of contents What is primary urethral cancer?... 3 Risk factors... 3 Symptoms... 4 Diagnosis... 4 Clinical examination... 4 Urinary cytology...
More informationThe Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary Study
The Journal of International Medical Research 2009; 37: 1823 1830 The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary
More informationGuidelines for the Management of Renal Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Renal Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Urinary tract infection: diagnosis, treatment and long-term management of urinary tract infection in children 1.1 Short title
More informationNICE guideline Published: 25 February 2015 nice.org.uk/guidance/ng2
Bladder cancer: diagnosis and management NICE guideline Published: 25 February 2015 nice.org.uk/guidance/ng2 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationEvidence Supporting the Recommendations. Implementation of the Guideline
Bladder cancer: diagnosis and management. Guideline Developer(s) National Collaborating Centre for Cancer Date Released 2015 Feb 25 Full Text Guideline Bladder cancer: diagnosis and management. (http://www.nice.org.uk/guidance/ng2)
More informationManagement of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.
Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.
More informationGUIDELINES FOR THE MANAGEMENT OF BLADDER CANCER
GUIDELINES FOR THE MANAGEMENT OF BLADDER CANCER For approvals and version control see Document Management Record on page 9 Ref: AngCN-SSG-U4 Page 1 of 11 Approved and Published: Aug 2012 TABLE OF CONTENTS
More informationDoes the Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Improve Survival in Bladder Cancer?
Does the Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Improve Survival in Bladder Cancer? Authors: Roderick Clark, 1 Kevin Wong, 2 Stacy Fan, 2 Joseph Chin, 1,3 Jonathan
More informationCarcinoma of the Renal Pelvis and Ureter Histopathology
Carcinoma of the Renal Pelvis and Ureter Histopathology Reporting Proforma (NEPHROURETERECTOMY AND URETERECTOMY) Includes the International Collaboration on Cancer reporting dataset denoted by * Family
More informationTHE USE OF HALF DOSE BCG FOR INTRAVESICAL IMMUNOTHERAPY IN NON MUSCLE INVASIVE BLADDER CANCER
THE USE OF HALF DOSE BCG FOR INTRAVESICAL IMMUNOTHERAPY IN NON MUSCLE INVASIVE BLADDER CANCER Mihály Zoltán Attila 1, Rusu Cristian Bogdan 2, Mihály Orsolya Maria 3, Bolboacă Sorana Daniela 4, Bungărdean
More informationEtiology and diagnosis of bladder cancer
Etiology and diagnosis of bladder cancer Introduction Incidence: the most common urothelial tumor, representing the 2 nd most common urological tumor in men (4 th in overall frequency) and the 1 st in
More informationTypes of bladder cancer
There are three main types of bladder cancer: Urothelial bladder cancer Squamous cell cancer Adenocarcinoma of the bladder There is more information about how we treat the different types of bladder cancer
More informationDOWNLOAD OR READ : URINARY ANALYSIS AND DIAGNOSIS BY MICROSCOPICAL AND CHEMICAL EXAMINATION CLASSIC REPRINT PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : URINARY ANALYSIS AND DIAGNOSIS BY MICROSCOPICAL AND CHEMICAL EXAMINATION CLASSIC REPRINT PDF EBOOK EPUB MOBI Page 1 Page 2 urinary analysis and diagnosis pdf ORIGINAL REPORT COMPARISON
More informationREFERRAL GUIDELINES: UROLOGY
All patients referred to specialist clinics are assigned to a priority category based on their clinical need and related psychosocial factors. The examples given are indicative only and the clinician reviewing
More informationOriginal Article APMC-276
Original Article APMC-276 The Clinical Value of Immediate Second Transurethral Resection in Patients with High Grade Non-Muscle Inasive Bladder Cancer (HG-NMIBC) Syed Saleem Abbas Jafri, Zafar Iqbal Khan
More informationBladder Cancer Diagnostic Tests
ISSN (Online): 1694-0784 ISSN (Print): 1694-0814 18 Bladder Cancer Diagstic Tests Shefali Jasra,Rishi Gupta, Shruti Mittal Lingayas Institute of Techlogy and Management Lingayas Institute of Techlogy and
More informationImproving Patient Outcomes: Optimal BCG Treatment Regimen to Prevent Progression in Superficial Bladder Cancer
european urology supplements 5 (2006) 654 659 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Improving Patient Outcomes: Optimal BCG Treatment Regimen to Prevent Progression
More informationBladder Cancer Early Detection, Diagnosis, and Staging
Bladder Cancer Early Detection, Diagnosis, and Staging Detection and Diagnosis Catching cancer early often allows for more treatment options. Some early cancers may have signs and symptoms that can be
More informationUrological Oncology INTRODUCTION. M Hammad Ather, Masooma Zaidi
Urological Oncology Predicting Recurrence and Progression in Non-Muscle- Invasive Bladder Cancer Using European Organization of Research and Treatment of Cancer Risk Tables M Hammad Ather, Masooma Zaidi
More informationReviewing Immunotherapy for Bladder Carcinoma In Situ
Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy
More informationBladder cancer (BC) is the fifth most commonly diagnosed malignancy in the United
1 Chapter 1: Background 1.1 Bladder Cancer Incidence and Etiology Bladder cancer (BC) is the fifth most commonly diagnosed malignancy in the United States, with more than 70,000 new cases and more than
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer
More informationMaintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk Non-muscle-invasive
Jpn J Clin Oncol 2013;43(3)305 313 doi:10.1093/jjco/hys225 Advance Access Publication 9 January 2013 Maintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk
More informationEuropean Association of Urology. Pocket Guidelines edition
European Association of Urology Pocket Guidelines 2012 edition Introduction The EAU Guidelines Office is pleased to present the 2012 edition of the Pocket Guidelines. These ultra-short versions of Europe
More informationImpingement syndrome. Clinical features. Management. Rotator cuff tear diagnosed. Go to rotator cuff tear
Impingement syndrome Clinical features Management Poor response Good response Refer to orthopaedic surgery R Review as appropriate Investigations Rotator cuff tear diagnosed Go to rotator cuff tear Consider
More informationUNDERSTANDING BLADDER CANCER
UNDERSTANDING BLADDER CANCER Learn About Your Treatment Options After Your Diagnosis If your doctor has told you that you have bladder cancer, you likely have many questions and concerns. Learning about
More informationBladder Cancer Knowing the Risks and Warning Signs. Part II: Warning Signs
Bladder Cancer Knowing the Risks and Warning Signs Part II: Warning Signs May 8, 2018 Presented by: is the Director of Urologic Oncology at MedStar Washington Hospital Center and an Assistant Professor
More informationUrology An introduction to cut up DR J R GOEPEL
Urology An introduction to cut up DR J R GOEPEL Overview Principles Individual organs Small pieces Partial resections Whole organs Data recording and data sets Principles You are working for the patient
More informationAppendix 4 Urology Care Pathways
Appendix 4 Urology Care Pathways Cancer Care Pathways outline the steps and stages in the patient journey from referral through to diagnostics, staging, treatment, follow up, rehabilitation and if applicable
More informationUrological Oncology. Dae Hyeon Kwon, Phil Hyun Song, Hyun Tae Kim.
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.7.457 Urological Oncology Multivariate Analysis of the Prognostic Significance of Resection Weight after Transurethral Resection of Bladder Tumor
More informationUROLOGY CANCER 2009 COMPARATIVE AUDIT REPORT
Urological Cancer Audit 2009 SOUTH EAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT UROLOGY CANCER 2009 COMPARATIVE AUDIT REPORT Dr Prasad Bollina, NHS Lothian SCAN Lead Urology Cancer Clinician Dr
More informationKyung Won Seo, Byung Hoon Kim, Choal Hee Park, Chun Il Kim, Hyuk Soo Chang
www.kjurology.org DOI:.4/kju..5..65 Urological Oncology The Efficacy of the EORTC Scoring System and Risk Tables for the Prediction of Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer after
More informationChronic kidney disease screening and assessment
Care map information Information resources for patients and carers Aboriginal and Torres Strait Islanders DEFINITION OF CKD egfr
More informationIntravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure
Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure Itay A. Sternberg, Guido Dalbagni,* Ling Y. Chen, Sherri M. Donat, Bernard H.
More informationGuidelines for Management of Penile Cancer
Guidelines for Management of Penile Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Versions 2 and 3 Sections 3, 5, 6 and 16 updated. Page 1 of 10 1. Scope
More informationPure non-bilharzial squamous cell carcinoma: An unusual form of carcinoma of the bladder
Safini et al. 31 case Series report peer Reviewed open OPEN ACCESS Pure non-bilharzial squamous cell carcinoma: An unusual form of carcinoma of the bladder Fatima Safini, Hassan Jouhadi, Meriem Elbachiri,
More informationEffective Health Care Program
Comparative Effectiveness Review Number 153 Effective Health Care Program Emerging Approaches to Diagnosis and Treatment of Non Muscle-Invasive Bladder Cancer Executive Summary Background Bladder cancer
More informationPart II: Treatment. A Woman-to-Woman Talk with Dr. Armine Smith. Wednesday, March 8, Presented by
Women & Bladder Cancer A Woman-to-Woman Talk with Dr. Armine Smith Wednesday, March 8, 2017 Part II: Treatment Presented by Dr. Smith is an Assistant Professor of Urology at Johns Hopkins University and
More informationIssues in the Management of High Risk Superficial Bladder Cancer
Issues in the Management of High Risk Superficial Bladder Cancer MICHAEL A.S. JEWETT DIVISION OF UROLOGY, DEPARTMENT OF SURGICAL ONCOLOGY, PRINCESS MARGARET HOSPITAL & THE UNIVERSITY OF TORONTO 1 Carcinoma
More information